RxDoctor Payments Data

Ashley Jeter, MD

Hematology & Oncology · North Charleston, SCNPI 1053518555

Payments from drug & device makers

$14,819in general payments, 2019–2025

Across 738 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$1K
  • Bristol Myers Squibb$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$755
  • AstraZeneca$724
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,68799%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis67$1,343
Merck59$1,274
Bristol Myers Squibb64$1,187
Johnson & Johnson55$1,116
E.r. Squibb & Sons, L.L.C.40$755
AstraZeneca(2 entities)38$724
Amgen32$658
Gilead(2 entities)25$568
Incyte Corporation25$559
Sanofi22$524
Pfizer27$448
Seagen Inc.20$377
GSK18$364
Array Biopharma Inc19$341
Genentech USA, Inc.18$304
Jazz Pharmaceuticals Inc.15$302
Astellas Pharma US Inc15$292
Takeda Pharmaceuticals U.S.A., Inc.11$275
Eisai Inc.14$275
Lilly USA, LLC13$271
Rigel Pharmaceuticals, Inc.9$245
Puma Biotechnology, Inc.11$173
AbbVie9$171
Daiichi Sankyo Inc.7$153
Regeneron Healthcare Solutions, Inc.6$147
Exelixis Inc.8$135
Pharmacyclics LLC, An Abbvie Company7$124
Karyopharm Therapeutics Inc.5$116
EMD Serono, Inc.6$106
AVEO Pharmaceuticals, Inc.4$103
Deciphera Pharmaceuticals Inc.4$97
Adaptive Biotechnologies Corporation4$95
Tersera Therapeutics LLC5$85
Stemline Therapeutics Inc.3$79
Beigene USA, Inc.5$79
Bayer4$71
Acrotech Biopharma Inc.3$67
Morphosys, US Inc.4$66
Sobi, Inc3$64
Taiho Oncology, Inc.3$60
Boehringer Ingelheim2$54
Heron Therapeutics, Inc.1$54
Novocure Inc.2$51
Kyowa Kirin, Inc.3$47
Mirati Therapeutics, Inc.2$45
G1 Therapeutics, Inc.2$42
ADC Therapeutics America, Inc.2$35
Epizyme, Inc.2$35
Dova Pharmaceuticals2$34
Ipsen Biopharmaceuticals, Inc1$28
Fennec Pharmaceuticals, Inc.1$24
EUSA Pharma (US) LLC1$24
CTI Biopharma Corp.1$18
Beone Medicines USA, Inc.1$17
Apellis Pharmaceuticals, Inc.1$16
Acceleron Pharma, Inc.1$16
Mylan Institutional Inc.1$15
Pharmacosmos Therapeutics Inc.1$15
Aurobindo Pharma USA, Inc.1$15
Sumitomo Pharma America, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,819 in reported general payments places this provider in the 60th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$102,167
Medicare patients
345
Services billed
1,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide64$1,131,186
XtandiEnzalutamide27$386,954
BrukinsaZanubrutinib24$355,826
PromactaEltrombopag Olamine19$330,586
JakafiRuxolitinib Phosphate20$315,492
CabometyxCabozantinib S-Malate12$289,719
VerzenioAbemaciclib19$274,626
Everolimus23$232,316
ImbruvicaIbrutinib13$212,772
TagrissoOsimertinib Mesylate13$206,361
BosulifBosutinib11$64,069
EliquisApixaban30$26,766
Abiraterone Acetate22$17,678
Anastrozole85$3,107
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$1,187$1,131,18664 claims
Astellas Pharma US IncXtandi$292$386,95427 claims
Beigene USA, Inc.Brukinsa$79$355,82624 claims
NovartisPromacta$1,343$330,58619 claims
Incyte CorporationJakafi$559$315,49220 claims
Exelixis Inc.Cabometyx$135$289,71912 claims
Lilly USA, LLCVerzenio$271$274,62619 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$124$212,77213 claims
AstraZenecaTagrisso$724$206,36113 claims
PfizerBosulif, Eliquis$448$90,83541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →